Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model
Further to our announcement of 24 September 2020 and further media comment the Company confirms that it remains in advanced negotiations with the UK Government and other partners for a
Cathal Friel, Executive Chairman, Open Orphan, said: This is very exciting news as we are now signing up such challenge study contracts on a regular basis .
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials notes
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
Open Orphan PLC are very excited about this new contract with a top 3 pharma company, this is a £4m RSV (respiratory syncytial virus) human challenge study clinical trial which
This RNS validates the refocus of Venn Life Sciences since Open Orphan took over the company last June to secure long-term partnership contracts which deliver recurring revenues for the business.
This RNS is the very exciting start to a substantial amount of COVID-19 work that we will be doing for the remainder of this year and throughout next year.
Cathal Friel, Executive Chairman of Open Orphan, said:
